| [1] |
LU Renquan, LIU Guangyu, YANG Wentao, GUO Lin, GUAN Ming, SHAO Zhimin, XU Dazhi, NI Ming, TANG Feng, WANG Chaofu, LOU Jiatao, SUN Fenyong, XING Jinliang, PAN Yueyin.
Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy
[J]. China Oncology, 2022, 32(1): 90-96.
|
| [2] |
ZHU Yihui, LI Ting, HU Xichun.
Clinical research progress and prospect of trastuzumab deruxtecan
[J]. China Oncology, 2021, 31(8): 754-761.
|
| [3] |
LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun .
miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene
[J]. China Oncology, 2021, 31(7): 581-588.
|
| [4] |
DING Gaofeng, GUO Leiming, LU Yufei.
The relationship between expressions of HER2 and BRCA1 and radiotherapy sensitivity in breast cancer patients
[J]. China Oncology, 2021, 31(7): 589-595.
|
| [5] |
YANG Jia , LIU Shuyuan , WANG Yingying , LI Yingfu , MA Qianli , LI Yu , WANG Yongrong , LI Chuanyin , TAN Fang .
The association of polymorphisms in TNF-α gene with non-small cell lung cancer in Han population of Yunnan Province
[J]. China Oncology, 2021, 31(7): 616-628.
|
| [6] |
Onco-endocrinology Society of Chinese Anti-Cancer Association, Onco-endocrinology Committee of Chongqing Association of Integrative Medicine.
Guidelines for the management of tumor-associated hyperglycemia (2021 edition)
[J]. China Oncology, 2021, 31(7): 651-688.
|
| [7] |
ZHANG Jian , SHEN Weina , JI Dongmei , WANG Leiping , GONG Chengcheng , HU Xichun .
FUSCC criteria for the management of targeted drug-induced interstitial lung disease in solid tumors
[J]. China Oncology, 2021, 31(4): 241-249.
|
| [8] |
YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying .
Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(3): 203-211.
|
| [9] |
GUO Ye , ZHANG Chenping .
Expert consensus on the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2021 edition)
[J]. China Oncology, 2021, 31(12): 1220-1232.
|
| [10] |
ZHAO Yuanyuan , ZHOU Jianying , FAN Yun , WANG Jialei , HUANG Dingzhi , LI Junling , SHI Meiqi , LIU Jiwei , YAO Yu , WU Lin , YAO Wenxiu , ZHANG Li .
Advances in the treatment of BRAF V600-mutant non-small cell lung cancer
[J]. China Oncology, 2021, 31(12): 1145-1152.
|
| [11] |
WU Qinan , TONG Nanwei .
Interpretation of Guidelines for the Management of Tumor-associated Hyperglycemia (2021 edition)
[J]. China Oncology, 2021, 31(12): 1153-1161.
|
| [12] |
PAN Jian, WEI Yu, YE Dingwei, ZHU Yao.
Correlation between EGFR (rs884419) gene polymorphism and clinicopathological characteristics of prostate cancer
[J]. China Oncology, 2021, 31(11): 1104-1109.
|
| [13] |
SHEN Yujia , FU Xiaolong .
Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer
[J]. China Oncology, 2021, 31(11): 1115-1125.
|
| [14] |
HE Xi, JIAO Xiaodong, ZANG Yuansheng.
Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(1): 69-75.
|
| [15] |
ZHU Lihua , NI Tingting , FAN Xingwen , WU Kailiang .
Comparison of prognostic scoring systems in patients with EGFR-mutant lung cancer and brain metastases
[J]. China Oncology, 2020, 30(8): 605-610.
|
